Wednesday, July 8, 2026

Patent intelligence · US

US 11786605

Site specific antibody-drug conjugates with peptide-containing linkers

granted A61KA61K2039/505A61K38/07A61K47/545
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 136
Patent details — US 11786605
Jurisdiction
US
Status
granted
Grant date
Oct 17, 2023
Expiration
Oct 12, 2043
Claims
8
CPC classes
A61K, A61K2039/505, A61K38/07, A61K47/545
View on Google Patents ↗

Quick answer

US 11786605 (Site specific antibody-drug conjugates with peptide-containing linkers) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Oct 17, 2023. Expires Oct 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
8
CPC classes
A61K, A61K2039/505, A61K38/07, A61K47/545, A61K47/65, A61K47/6803

More from Mersana Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12427199

    Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

    RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI · Expires Sep 25, 2045

    granted
  2. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Sanaria Inc. · Expires Sep 4, 2045

    granted
  3. US 12246059

    Stable hybrid FC fusion G-CSF formulation

    ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Expires Mar 6, 2045

    granted
  4. US 12171822

    Infectious plasmodium sporozoites grown in vitro

    Sanaria Inc. · Expires Dec 19, 2044

    granted
  5. US 12156870

    Antibody drug conjugates comprising sting agonists

    Mersana Therapeutics, Inc. · Expires Nov 28, 2044

    granted
  6. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Sanabio, LLC · Expires Oct 24, 2044

    granted
  7. US 12077543

    P2X3 and/or P2X2/3 compounds and methods

    Asana BioSciences, LLC · Expires Aug 29, 2044

    granted
  8. US 11987628

    Methods and compositions for modulating CAR-T activity

    Sana Biotechnology, Inc. · Expires May 16, 2044

    granted

Frequently asked questions

What is US patent 11786605?

US 11786605 (Site specific antibody-drug conjugates with peptide-containing linkers) is held by Mersana Therapeutics, Inc.. Status: granted. Granted Oct 17, 2023. Expires Oct 12, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11786605?

Mersana Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.

When does US 11786605 expire?

Our index shows an expiration date of Oct 12, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.